Brief: Erytech Completes First Cohort In Phase 1 Investigator Trial Of Eryaspase

Phaxiam Therapeutics SA

19/04/2021 06:39

April 19 (Reuters) - ERYTECH PHARMA SA  ERYP.PA :
    * ANNOUNCES COMPLETION OF FIRST COHORT IN A PHASE 1
INVESTIGATOR
SPONSORED TRIAL OF ERYASPASE IN FIRST-LINE PANCREATIC CANCER
    * NO DOSE-LIMITING TOXICITY REPORTED IN FIRST DOSE COHORT
    * ENCOURAGING CLINICAL ACTIVITY OBSERVED IN FIRST PATIENTS
    * TRIAL WILL BE ESCALATED TO NEXT DOSE
    * TRIAL WILL NOW BE ESCALATED TO NEXT COHORT, WHERE DOSE
LEVEL
WILL BE INCREASED TO 100 U/KG ERYASPASE

Source text for Eikon:  ID:nGNX7mBpDh 
Further company coverage:  ERYP.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))